Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Methods for treating skeletal muscle cachexia arising from burn injury by administering PDE4B-selective inhibitors
US11052085B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11052085-B2 |
| Application number | US-201816202878-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 28, 2018 |
| Priority date | Nov 28, 2017 |
| Publication date | Jul 6, 2021 |
| Grant date | Jul 6, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method of treating skeletal muscle cachexia and inflammation associated with burn injury in a subject in need thereof is provided, the method including administering to the subject an effective amount of a phosphodiesterase-4B (PED4B)-selective inhibitor.
First claim
Opening claim text (preview).
We claim: 1. A method of treating skeletal muscle cachexia associated with burn injury in a subject in need thereof, the method comprising administering to the subject an effective amount of a phosphodiesterase-4B (PDE4B)-selective inhibitor selected from the group consisting of (4-{[2-(5-Chloro-2-thienyl)-5-ethyl-6-methyl-4-pyrimidinyl]amino}phenyl)acetic acid, (4-{[5-Ethyl-2-(5-fluoro-2-thienyl)-6-methyl-4-pyrimidinyl]amino}-3-fluorophenyl)acetic acid, and combinations thereof. 2. The method according to claim 1 , wherein the PDE4B-selective inhibitor comprises a compound that acts by closing a control region 3 (CR3)C-terminal regulatory domain across an active site of PDE4B, thereby inhibiting PDE4B. 3. The method according to claim 1 , further comprising administering to the subject an effective amount of a phosphodiesterase-5 (PDE5) inhibitor selected from the group consisting of avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, vardenafil, udenafil, zaprinast, benzamidenafil, and dasantafil. 4. The method according to claim 3 , wherein the PDE4B-selective inhibitor and the PDE5 inhibitor are administered contemporaneously or sequentially. 5. The method according to claim 1 , wherein the subject is a mammal. 6. The method according to claim 5 , wherein the subject is selected from the group consisting of mouse, rat, rabbit, monkey, pig, and human. 7. The method according to claim 6 , wherein the subject is a human.
Assignees
Inventors
Classifications
having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495}) · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Drugs for disorders of the muscular or neuromuscular system · CPC title
having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir · CPC title
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11052085B2 cover?
- A method of treating skeletal muscle cachexia and inflammation associated with burn injury in a subject in need thereof is provided, the method including administering to the subject an effective amount of a phosphodiesterase-4B (PED4B)-selective inhibitor.
- Who is the assignee on this patent?
- Univ Cincinnati, Shriners Hospitals Children
- What technology area does this patent fall under?
- Primary CPC classification A61K31/506. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).